Follow
Sophie Sneddon
Sophie Sneddon
Michael Smith Genome Sciences Centre
Verified email at bcgsc.ca
Title
Cited by
Cited by
Year
Comparison of the Diagnostic Accuracy of the MSLN Gene Products, Mesothelin and Megakaryocyte Potentiating Factor, as Biomarkers for Mesothelioma in …
J Creaney, S Sneddon, IM Dick, H Dare, N Boudville, AW Musk, SJ Skates, ...
Disease markers 35, 119-127, 2013
382013
Absence of germline mutations in BAP1 in sporadic cases of malignant mesothelioma
S Sneddon, JS Leon, IM Dick, G Cadby, N Olsen, F Brims, RJN Allcock, ...
Gene 563 (1), 103-105, 2015
372015
Whole exome sequencing of an asbestos-induced wild-type murine model of malignant mesothelioma
S Sneddon, AM Patch, IM Dick, S Kazakoff, JV Pearson, N Waddell, ...
BMC cancer 17, 1-10, 2017
342017
Strong spontaneous tumor neoantigen responses induced by a natural human carcinogen
J Creaney, S Ma, SA Sneddon, MR Tourigny, IM Dick, JS Leon, A Khong, ...
Oncoimmunology 4 (7), e1011492, 2015
322015
Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma
J Creaney, AM Patch, V Addala, SA Sneddon, K Nones, IM Dick, YCG Lee, ...
Genome Medicine 14 (1), 58, 2022
302022
Malignant cells from pleural fluids in malignant mesothelioma patients reveal novel mutations
S Sneddon, I Dick, YCG Lee, AWB Musk, AM Patch, JV Pearson, ...
Lung Cancer 119, 64-70, 2018
262018
Identification of a CD8+ T-cell response to a predicted neoantigen in malignant mesothelioma
S Sneddon, CM Rive, S Ma, IM Dick, RJN Allcock, SD Brown, RA Holt, ...
Oncoimmunology 9 (1), 1684713, 2020
152020
Characterization of the immune cell landscape in CRC: clinical implications of tumour-infiltrating leukocytes in early-and late-stage CRC
ZA Bazzi, S Sneddon, PGY Zhang, IT Tai
Frontiers in Immunology 13, 978862, 2023
72023
The use of whole exome sequencing and murine patient derived xenografts as a method of chemosensitivity testing in sarcoma
N Calvert, J Wu, S Sneddon, J Woodhouse, R Carey-Smith, D Wood, ...
Clinical sarcoma research 8, 1-8, 2018
42018
BAP1 mutations in mesothelioma: advances and controversies
S Sneddon, J Creaney
Current Pulmonology Reports 5, 13-19, 2016
12016
89P Dissecting tumour-immune interactions in mesothelioma for identifying responders to immune checkpoint blockade
V Addala, S Sneddon, I Dick, D Fennell, JV Pearson, B Robinson, ...
Annals of Oncology 31, S1453, 2020
2020
Molecular characterisation of murine and human malignant mesothelioma and the identification of neoantigens as potential targets for therapy using next generation sequencing
S Sneddon
2017
GENETIC PROFILING OF MALIGNANT MESOTHELIOMA IN PLEURAL EFFUSIONS SHOWS HIGH VARIABILITY
S Sneddon, S Brown, R Holt, B Robinson, J Creaney
RESPIROLOGY 21, 48-48, 2016
2016
Use of Next Generation Sequencing to Improve Lung Tumor Immunotherapy
BWS Robinson, S Ma, S Sneddon, MR Tourigny, I Dick, JS Leon, A Khong, ...
JOURNAL OF THORACIC ONCOLOGY 10 (9), S351-S351, 2015
2015
Understanding the Genetic Landscape of Malignant Mesothelioma-A Comparison of Human and Murine Mesothelioma Cell Lines
J Creaney, S Sneddon, N Waddell, J Pearson, S Grimmond, ...
JOURNAL OF THORACIC ONCOLOGY 10 (9), S504-S504, 2015
2015
University of Tasmania Open Access Repository Cover sheet
AD Lynch
Papers and Proceedings of the Royal Society of Tasmania 128, 17, 1994
1994
–Whole exome sequencing of a wild-type asbestos-induced murine model of malignant mesothelioma
S Sneddon, AM Patch, IM Dick, S Kazakoff, JV Pearson, N Waddell, ...
Molecular characterisation of murine and human malignant mesothelioma and …, 0
Next generation sequencing of pleural effusion tumour cells in malignant mesothelioma identifies novel regions of interest
S Sneddon, I Dick, YCG Lee, AWB Musk, N Waddell, AM Patch, ...
Molecular characterisation of murine and human malignant mesothelioma and …, 0
Appendix–Two published papers related to the work in this thesis
S Sneddon
Molecular characterisation of murine and human malignant mesothelioma and …, 0
The system can't perform the operation now. Try again later.
Articles 1–19